Cargando…

Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors

The treatment landscape of advanced non-small cell lung cancer (NSCLC) has changed dramatically since the emergence of immune checkpoint inhibitors (ICIs). Although some patients achieve long survival with relatively mild toxicities, not all patients experience such benefits from ICI treatment. Ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakagawa, Natsuki, Kawakami, Masanori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414869/ https://www.ncbi.nlm.nih.gov/pubmed/36033471 http://dx.doi.org/10.3389/fonc.2022.952393

Ejemplares similares

Metabolic barriers in non-small cell lung cancer with LKB1 and/or KEAP1 mutations for immunotherapeutic strategies
por: Tanaka, Ichidai, et al.
Publicado: (2023)

Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy
por: Meyers, Daniel E., et al.
Publicado: (2017)

Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges
por: Perutelli, Francesca, et al.
Publicado: (2022)

Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer
por: Patel, Shabnum, et al.
Publicado: (2019)

Targeting Versican as a Potential Immunotherapeutic Strategy in the Treatment of Cancer
por: Hirani, Priyanka, et al.
Publicado: (2021)

Mathematical analysis identifies the optimal treatment strategy for epidermal growth factor receptor-mutated non-small cell lung cancer
por: Yu, Qian, et al.
Publicado: (2023)

Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer
por: Martin, Claudio, et al.
Publicado: (2022)

Immunotherapeutic Advancements for Glioblastoma
por: Ampie, Leonel, et al.
Publicado: (2015)

Serum cytokine levels and other associated factors as possible immunotherapeutic targets and prognostic indicators for lung cancer
por: Zhao, Yinghao, et al.
Publicado: (2023)

Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer
por: Zhang, Xiaofei, et al.
Publicado: (2023)

Immunotherapeutic Potential of Oncolytic Vaccinia Virus
por: Thorne, Steve H.
Publicado: (2014)

Experiences and Expectations for Glioma Immunotherapeutic Approaches
por: Yamanaka, Ryuya, et al.
Publicado: (2014)

Immunotherapeutic Potential of T Memory Stem Cells
por: Li, Yujie, et al.
Publicado: (2021)

Budd-Chiari syndrome and its associated hepatocellular carcinoma: Clinical risk factors and potential immunotherapeutic benefit analysis
por: Li, Kang-Shuai, et al.
Publicado: (2022)

Attenuated Bacteria as Immunotherapeutic Tools for Cancer Treatment
por: Kaimala, Suneesh, et al.
Publicado: (2018)

Development and validation of a mutation-based model to predict immunotherapeutic efficacy in NSCLC
por: He, Ping, et al.
Publicado: (2023)

The Power to Choose
por: Greenfeld, Yeshayahu
Publicado: (2018)

Glioma Stem Cells as Immunotherapeutic Targets: Advancements and Challenges
por: Piper, Keenan, et al.
Publicado: (2021)

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
por: Pan, Yue, et al.
Publicado: (2021)

Therapeutic strategies for BRAF mutation in non-small cell lung cancer: a review
por: Puri, Megha, et al.
Publicado: (2023)

Editorial: Prognostic factors in non-small cell lung cancer
por: Rahouma, Mohamed, et al.
Publicado: (2023)

Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
por: Désage, Anne-Laure, et al.
Publicado: (2022)

State-of-the-art combination treatment strategies for advanced stage non–small cell lung cancer
por: Yao, Yongfang, et al.
Publicado: (2022)

Immunotherapeutic Targeting of GPC3 in Pediatric Solid Embryonal Tumors
por: Ortiz, Michael V., et al.
Publicado: (2019)

T Lymphocytes: A Promising Immunotherapeutic Target for Pancreatitis and Pancreatic Cancer?
por: Zhou, Qi, et al.
Publicado: (2020)

CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma
por: Sussman, Robyn T., et al.
Publicado: (2020)

The Diagnostic and Immunotherapeutic Value of CD248 in Renal Cell Carcinoma
por: Zhang, Keying, et al.
Publicado: (2021)

Identification and validation of a novel phagocytosis regulators-related signature with potential prognostic and immunotherapeutic value in patients with lung adenocarcinoma
por: Li, Jingyang, et al.
Publicado: (2022)

Editorial: Factors that impact the survival of non-small cell lung cancer
por: Hegi-Johnson, Fiona, et al.
Publicado: (2023)

Multi-spectral immunofluorescence evaluation of the myeloid, T cell, and natural killer cell tumor immune microenvironment in chordoma may guide immunotherapeutic strategies
por: Lopez, Diana C., et al.
Publicado: (2022)

Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1
por: Moehler, Markus, et al.
Publicado: (2014)

Prognostic Biomarkers and Immunotherapeutic Targets Among CXC Chemokines in Pancreatic Adenocarcinoma
por: Huang, Jiacheng, et al.
Publicado: (2021)

Cuproplasia characterization in colon cancer assists to predict prognosis and immunotherapeutic response
por: Zhang, Bomiao, et al.
Publicado: (2023)

Strategies of Dose Escalation in the Treatment of Locally Advanced Non-Small Cell Lung Cancer: Image Guidance and Beyond
por: Chi, Alexander, et al.
Publicado: (2014)

Monomerization of ALK Fusion Proteins as a Therapeutic Strategy in ALK-Rearranged Non-small Cell Lung Cancers
por: Hirai, Noriko, et al.
Publicado: (2020)

TIGIT-based immunotherapeutics in lung cancer
por: Patel, Akshay J, et al.
Publicado: (2023)

Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic
por: Friedlaender, Alex, et al.
Publicado: (2020)

The Survival Benefit for Optimal Glycemic Control in Advanced Non-Small Cell Lung Cancer Patients With Preexisting Diabetes Mellitus
por: Qian, Jie, et al.
Publicado: (2021)

Exploration of the Prognostic and Immunotherapeutic Value of B and T Lymphocyte Attenuator in Skin Cutaneous Melanoma
por: Dong, Xubin, et al.
Publicado: (2021)

Cancel cancer: The immunotherapeutic potential of CD200/CD200R blockade
por: Choe, Deborah, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jp0t3d2oh22a38ib5u03cnpd95